41 results about "Valerate" patented technology

The invention discloses a pure bio-based polyhydroxyalkanoate adhesive as well as preparation and application thereof, and belongs to the technical field of degradable adhesives. According to the adhesive, polyhydroxybutyrate valerate or polyhydroxybutyrate hexanoate is used as a matrix, and the acid value reaches 2-15 mg KOH / g through molten end group activation; a reactive emulsifier with a hydrophilic-lipophilic balance value of 9-12 is introduced into a water phase, and the stable aqueous dispersion is prepared through phase inversion high-shear emulsification. The Z-average particle size of the dispersion is 0.12-0.30 [mu] m, and the content of the free surfactant is not higher than 30wt%. After the tackifying resin, the plasticizer and the vegetable wax are compounded, the bio-based carbon content of the obtained adhesive is not lower than 95%, and the volatile organic compound content is not higher than 100 mg / kg. The paper / paper heat sealing strength of the adhesive is not lower than 7.0 N / 15mm, the 180-degree peel strength is not lower than 7.5 N / 25mm, and the adhesive can pass repulping evaluation.

The invention discloses a synthesis method of 2-bromomethyl-5-trifluoromethyl furan, which comprises the following steps: S1, carrying out reaction on acetoacetate and halogenated trifluoroacetone under the action of an alkaline substance and a catalyst to generate a 2-acetyl-5, 5, 5-trifluoro-4-oxovalerate crude product; s2, carrying out a cyclization reaction on the 2-acetyl-5, 5, 5-trifluoro-4-oxovalerate crude product, so as to obtain a 2-methyl-5-(trifluoromethyl) furan-3-formate crude product, and carrying out a cyclization reaction on the 2-acetyl-5, 5, 5-trifluoro-4-oxovalerate crude product to obtain a 2-methyl-5-(trifluoromethyl) furan-3-formate crude product; s3, adding an alkaline substance into the crude product, carrying out hydrolysis, and adding acid to adjust the pH value after the hydrolysis is completed, so as to obtain 2-methyl-5-(trifluoromethyl) furan-3-formic acid; s4, the 2-methyl-5-(trifluoromethyl) furan-3-formic acid is subjected to a heating decarboxylation reaction, and 2-methyl-5-(trifluoromethyl) furan is obtained; and S5, carrying out a bromination reaction on the 2-methyl-5-(trifluoromethyl) furan and a bromination reagent to obtain a final product 2-bromomethyl-5-(trifluoromethyl) furan. The raw materials used in the synthesis method are easy to obtain, use of control chemicals is not involved, and industrialization is easy to achieve.

The invention discloses a composite medical suture and a preparation method thereof, and belongs to the field of biomedicine. In order to solve the problems that an existing medical suture is poor in antibacterial effect and biological safety, the composite medical suture comprises a core layer, a degradation regulation and control layer, a slow release layer and an antibacterial layer which are sequentially arranged from inside to outside; the core layer is prepared from a blend fiber of poly (hydroxybutyrate-hydroxyvalerate) and polycaprolactone-co-polyglycolide; the degradation regulation and control layer comprises a mixture of at least two kinds of polyethylene glycol with different molecular weights; the slow release layer comprises quaternary ammonium salt loaded graphene oxide nanofibers; the antibacterial layer comprises titanium dioxide loaded with silver nanoparticles. Through the synergistic effect of the four layers, the comprehensive optimization of mechanical properties, degradation rate, drug sustained release and antibacterial function is realized; the purposes of improving the slow-release antibacterial performance, reducing damage to the human body, reducing inflammation and the like are achieved, and the antibacterial and degradation effects meet the recovery requirements.

The present invention relates to a composition comprising at least one mixture of organic peroxides containing a first organic peroxide of formula (I) and a second organic peroxide, n-butyl-4,4-di(tert-butylperoxy)-valerate. The invention also relates to the use of said composition for crosslinking at least one crosslinkable polymer.

A full continuous-flow preparation method of (+)-biotin, including: subjecting a cyclic anhydride and a chiral biphenyl propylene glycol to asymmetric ring-opening reaction to produce a first intermediate, which undergoes selective reduction with a borohydride and cyclization with an inorganic mineral acid to produce (3aS, 6aR)-lactone; subjecting the (3aS, 6aR)-lactone and a sulfenylating reagent to sulfenylation to produce (3aS, 6aR)-thiolactone, which undergoes Fukuyama coupling with a zinc reagent in the presence of a palladium catalyst and elimination reaction in the presence of an inorganic mineral acid to produce an alkenyl valerate compound; subjecting the alkenyl valerate compound to reduction in the presence of a Pd / C catalyst to produce a valerate ester, which undergoes hydrolysis to produce a valeric acid salt; and subjecting the valeric acid salt to debenzylation in the presence of an inorganic mineral acid to produce the target product (+)-biotin.

The present invention discloses a composite medical suture and a preparation method thereof, which belong to the field of biomedicine. In view of the problems of poor antibacterial effect and biosafety of existing medical sutures, the present invention provides a composite medical suture, comprising a core layer, a degradation regulating layer, a sustained-release layer and an antibacterial layer arranged in sequence from the inside to the outside; the core layer comprises a blended fiber of polyhydroxybutyrate-valerate copolyester and polycaprolactone-co-glycolide; the degradation regulating layer comprises a mixture of at least two polyethylene glycols of different molecular weights; the sustained-release layer comprises quaternary ammonium salt-loaded graphene oxide nanofibers; the antibacterial layer comprises titanium dioxide loaded with silver nanoparticles. The present invention achieves comprehensive optimization of mechanical properties, degradation rate, drug sustained release and antibacterial function through the synergistic effect between the four layers; achieves the purpose of improving sustained-release antibacterial performance, reducing damage to the human body and reducing the occurrence of inflammation, etc., so that its antibacterial and degradation effects meet recovery requirements.

The application discloses a preparation method of 2-ethyl-2-methyl pentanoic acid, wherein in the process of preparing a key intermediate 2-cyanopentanoate (compound B), compound A is removed by using an alkali extraction method, high-purity compound B is separated by using rectification (a yield of 20% and a purity of 98%), and the operation process is simple. In the preparation method, reagents used are sodium methoxide, sodium hydroxide, sulfuric acid, sodium hydride and sodium nitrite, the reagents are simple, the danger is relatively small, and the experimental operation is relatively safe. In the preparation method, the post-treatment processes of alkylation, hydrolysis, deacidification and cyano hydrolysis do not use a chromatographic column purification process, and a conventional extraction distillation operation is adopted, so that the output of unit volume of instrument equipment is high.

The disclosure relates to forms of 5-[(3-{2-[bis(propan-2-yl)azaniumyl]ethyl}-1H-indol-4-yl)oxy]-5-oxopentanoate, including solvates such as methanol 5-[(3-{2-[bis(propan-2-yl)azaniumyl]ethyl}-1H-indol-4-yl)oxy]-5-oxopentanoate (also referred to as 4-glutarato-N,N-diisopropyltryptamine methanol solvate or 4-glutarato-DiPT·MeOH), and crystalline forms thereof such as crystalline form 1 of 4-glutarato-DiPT·MeOH and ethanol 5-[(3-{2-[bis(propan-2-yl)azaniumyl]ethyl}-1H-indol-4-yl)oxy]-5-oxopentanoate (4-glutarato-N,N-diisopropyltryptamine ethanol solvate or 4-glutarato-N,N-DiPT·EtOH), crystalline 4-glutarato-N,N-DiPT·EtOH, and crystalline forms thereof, including crystalline form 1 of 4-glutarato-N,N-DiPT·EtOH; and to pharmaceutical compositions containing them and to methods of treatment using them. The disclosure further relates to crystalline [3-[2-(methylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate (baeocystin), such as crystalline form 1 of baeocystin, and to pharmaceutical compositions containing crystalline baeocystin, such as crystalline form 1 of baeocystin, and to methods of treatment using it.

The present invention discloses a fully continuous flow preparation method for (+)-biotin. The method comprises: performing an asymmetric ring-opening reaction on a cyclic anhydride and a biphenyl chiral propylene glycol, performing a selective reduction reaction on the product with a borohydride, and then performing a cyclization reaction with an inorganic mineral acid to obtain (3a S ,6a R ) lactone; (3a S ,6a R ) The lactone undergoes a thiolation reaction with a thio reagent, the product then undergoes a Fukuyama coupling reaction with a zinc reagent in the presence of a palladium catalyst, the product undergoes an elimination reaction in the presence of an inorganic mineral acid to obtain an alkenyl valerate compound; the alkenyl valerate compound is reduced in the presence of a palladium / carbon catalyst to obtain a valerate ester; a hydrolysis reaction is performed to obtain a valerate salt; and the valerate salt undergoes a debenzylation reaction in the presence of an inorganic mineral acid. The process of the present invention is carried out continuously, the total time is greatly shortened, the total yield is increased to 48.7%, the degree of automation is high, the time-space yield is high, and the method is suitable for industrial production.

Provided are a salt and / or a crystal form of a compound degrading BTK and preparation and application thereof. The pharmaceutically acceptable salt and crystal form of the compound as shown in formula (I), wherein the pharmaceutically acceptable salt is selected from a maleate salt, a fumarate salt, a hydrogen halide salt (preferably a hydrobromide salt and a hydrochloride salt), a sulfate salt, a phosphate salt, an L-tartrate salt, a citrate salt, an L-malate salt, a hippurate salt, a D-glucuronate salt, a glycolate salt, a mucate salt, a succinate salt, a lactate salt, an orotate salt, a pamoate salt, a glycine salt, an alanine salt, an arginine salt, a cinnamate salt, a benzoate salt, a benzene sulfonate salt, a p-toluene sulfonate salt, an acetate salt, a propionate salt, a valerate salt, a triphenylacetic acid salt, an L-proline salt, a ferulic acid salt, a 2-hydroxyethanesulfonate salt, a mandelate salt, a nitrate salt, a methanesulfonate salt, a malonate salt, a gentisate salt, a salicylate salt, an oxalate salt or a glutarate salt:

The application discloses cupriavidus capable of producing polyhydroxyalkanoate by using various carbon sources such as ethanol and application thereof. Cupriavidus The strain sp.ZWJ01 has a preservation number of CGMCC No.37462 in the China General Microbiological Culture Collection Center. The strain can grow and accumulate poly-3-hydroxybutyric acid ester by using various substances such as ethanol, volatile fatty acid and sugar as carbon sources; can grow by using mixed carbon sources of ethanol+propionic acid or ethanol+valeric acid and accumulate poly(3-hydroxybutyric acid-co-3-hydroxyvaleric acid ester) in cells; and can grow by using mixed carbon sources of ethanol+gamma-butyrolactone or ethanol+1,4-butanediol and accumulate poly(3-hydroxybutyric acid-co-4-hydroxybutyric acid) in cells, and has a good application prospect.

This application relates to a degradable blister sheet, a preparation method thereof, and a blister product. The degradable blister sheet comprises the following components in percentage by weight: 30%-65% of polyhydroxyalkanoate, 10%-35% of inorganic powder, 5%-20% of poly(methyl ethylene carbonate), 1%-5% of small molecule lubricant, 0.2%-1% of nucleating agent, and 0.5%-3% of inorganic color powder; wherein, the polyhydroxyalkanoate comprises one or more of polyhydroxybutyrate, hydroxybutyrate valerate copolyester, hydroxybutyrate hexanoate copolyester, and poly(3-hydroxybutyrate-4-hydroxybutyrate) copolymer; the inorganic powder comprises one or more of talc, diatomite, kaolin, calcium carbonate, and barium sulfate. The degradable blister sheet provided by this application can be naturally degraded in nature, which is beneficial to alleviating plastic pollution and reducing the harm of plastic use to the natural environment.

This invention discloses a method for synthesizing α-hydroxycarboxylic acid compounds. The method includes the following steps: adding a reaction substrate, a photosensitizer, and a base to a dry reaction tube; then adding a solvent and additives under a CO2 atmosphere; and reacting under visible light irradiation. After the reaction is complete, the reaction system is acidified and quenched, and then purified to obtain the product, the α-hydroxycarboxylic acid compound. The photosensitizer includes Ir(ppy)2(dtbbpy)PF6 and 3DPA2FBN; the base is potassium tert-butoxide, cesium carbonate, or potassium tert-valerate; the additives are N,N-diisopropylethylamine and chlorosilane; and the reaction substrate is an aldehyde or ketone compound. This invention provides a highly efficient and selective synthesis of α-hydroxycarboxylic acid compounds under visible light induction and a CO2 atmosphere. The reaction conditions of this invention are mild, the reactant range is broad, the selectivity is good, and it can be scaled up to the gram scale.

The invention discloses preparation and application of a material with mechanical properties insensitive to a deformation rate, and belongs to the technical field of high polymer materials, 2-hydroxyethyl-5-(1, 2-dithiolane-3-yl) valerate is selected as a monomer, N, N-dimethylformamide is used as a solvent and a catalyst, the N, N-dimethylformamide is volatilized to induce the 2-hydroxyethyl-5-(1, 2-dithiolane-3-yl) valerate to react with the deformation rate, and the mechanical properties of the material are insensitive to the deformation rate. The preparation method comprises the following steps: polymerizing 1, 2-dithiolane-3-yl) valerate to form a linear polymer and a cyclic polymer, and dialyzing by using tetrahydrofuran to remove the residual monomer and linear polymer, thereby obtaining the lantern ring material of which the mechanical property is insensitive to the deformation rate. The material with the mechanical property insensitive to the deformation rate has the advantages that the mechanical property is insensitive to strain, the preparation is simple, the mechanical property is controllable and the like, has a wide application prospect in the aspects of electronic insulating layers, automobile and rail transit, deep sea engineering and the like, and is simple and feasible in synthesis process, wide in application range, low in preparation cost and easy to popularize.

This invention belongs to the fields of medicinal chemistry and organic synthesis, specifically relating to a stable 3-aminocyclobutane-1,1-dicarboxylic acid diethyl oxalate and its application in the preparation of 3-(cholate-valerate)cyclobutane-1,1-dicarboxylic acid. This invention effectively solves the technical bottlenecks of poor stability, difficulty in purification, and storage by converting unstable free 3-aminocyclobutane-1,1-dicarboxylic acid diethyl oxalate into a specific organic acid salt form. More importantly, this invention discovers that this organic acid salt can be directly used as a reaction intermediate, and can be used efficiently in subsequent amide condensation reactions with cholic acid or its active derivatives without the separation of free amines. This method significantly improves the purity and yield of the key intermediate and its downstream product 3-(cholate-valerate)cyclobutane-1,1-dicarboxylic acid. The process is stable and simple to operate, providing a stable, controllable, and economical preparation route for the industrial production of 3-(cholate-valerate)cyclobutane-1,1-dicarboxylic acid, a key active pharmaceutical ingredient in the liver cancer prodrug LLC-202.

To provide a heat storable substance which can form a semi-clathrate hydrate without presence of a halogen element.SOLUTION: Provided is a heat storable substance comprising an ionic material and water, in which the ionic material includes at least one cation selected from a group consisting of tri-n-butyl n-hexyl ammonium cation, tri-n-butyl n-pentyl phosphonium cation, and tri-n-butyl n-hexyl phosphonium cation, and at least one anion selected from a group consisting of acetate ions, propionate ions, butyrate ions, valerate ions, isovalerate ions, and acrylate ions.SELECTED DRAWING: None

The disclosure relates to forms of 5-[(3-{2-[bis(propan-2-yl)azaniumyl]ethyl}-1H-indol-4-yl)oxy]-5-oxopentanoate, including solvates such as methanol 5-[(3-{2-[bis(propan-2-yl)azaniumyl]ethyl}-1H-indol-4-yl)oxy]-5-oxopentanoate (also referred to as 4-glutarato-N,N-diisopropyltryptamine methanol solvate or 4-glutarato-DiPT-MeOH), and crystalline forms thereof such as crystalline form 1 of 4-glutarato-DiPT-MeOH and ethanol 5-[(3-{2-[bis(propan-2-yl)azaniumyl]ethyl}-1H-indol-4-yl)oxy]-5-oxopentanoate (4-glutarato-N,N-diisopropyltryptamine ethanol solvate or 4-glutarato-N,N-DiPT-EtOH), crystalline 4-glutarato-N,N-DiPT-EtOH, and crystalline forms thereof, including crystalline form 1 of 4-glutarato-N,N-DiPT-EtOH; and to pharmaceutical compositions containing them and to methods of treatment using them. The disclosure further relates to crystalline [3-[2-(methylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate (baeocystin), such as crystalline form 1 of baeocystin, and to pharmaceutical compositions containing crystalline baeocystin, such as crystalline form 1 of baeocystin, and to methods of treatment using it.

The application discloses a method for preparing methyl valerate by butene carbonylation, and belongs to the field of catalytic chemistry. Raw materials containing butene, carbon monoxide and methanol are introduced into a reactor loaded with a solid acid catalyst, and a product containing methyl valerate is obtained through reaction. The application provides a new method for preparing methyl valerate by butene carbonylation with a solid acid catalyst. The method for preparing methyl valerate has the advantages of cheap and easily obtained raw materials, small corrosion of the system, easy separation of the product, less waste discharge, easy engineering of the fixed bed process, and suitability for single large-scale production.

Methods and consumer products for detecting a metabolite, the method comprising: testing a urine sample from a subject for a metabolite selected from the group consisting of ascorbate, dehydroascorbate, CEHC-sulfate, CEHC-taurine, CEHC-glucronide, pantoate, 5-amino valerate, galactonate, phenylacetylalanine, methylcatecholsulfate, phenylacetylglutamine, carboxysuccinate, carboxyethylvaline, arabinose, threonate, methylcrotonylglycine, glucuronate, carboxyethylisoleucine, glycoursodeoxycholate, leucylalanine, lithocholatesulfate, allo-threonine, cholic, glucuronide and combinations thereof; and producing a metabolic profile for the metabolite.

The invention belongs to the technical field of organic chemistry, and particularly relates to a preparation process of rucotinib phosphate. The preparation process comprises the following steps: carrying out Suzuki coupling reaction on 1-(1-ethoxyethyl)-4-pyrazol boronic acid pinacol ester and (4-chloro-7H-pyrrolo [2, 3-D] pyrimidine-7-yl) methyl pivalate, carrying out acidification treatment, carrying out addition reaction, carrying out chiral resolution treatment, carrying out deprotection treatment, carrying out salt forming reaction and carrying out corresponding post-treatment. According to the preparation process disclosed by the invention, the rucotinib phosphate with high yield and high purity can be prepared.

The utility model discloses a lipoic acid preparation device, which relates to the technical field of synthesis and comprises a cold medium inlet, a cold medium outlet, a paddle and a reaction kettle, a jacket is sleeved outside the reaction kettle, the top of one end of the jacket is communicated with the cold medium inlet, and the top of the other end of the jacket is communicated with the cold medium outlet. A vacuum valve is arranged on one side of the cold medium inlet, air can be discharged out of a reaction system by ventilating the reaction kettle, and a reducing gas sulfur dioxide is added, so that the generation of impurities can be reduced, and a by-product ethyl 1, 2, 3-trithiahexane-4-valerate can be directly reduced into lipoic acid in the reaction process. According to the method, the reaction steps are greatly simplified, the yield and the purity of the product are improved, the reaction can be completed at a lower temperature in a short time (within 1 hour) through the ball-milling reaction in combination with a cooling environment, and the generation of by-products can be reduced due to the low temperature.

The present invention relates to an improved process for the preparation of (((1-(6-amino-9H-purin-9-yl)propan-2-yloxy)methyl)(phenoxy)phosphoryloxy)methyl pivalate Compound (1) or its pharmaceutically acceptable salts thereof. The compound is useful as nucleotide reverse transcriptase inhibitor in therapy for diseases which respond to inhibition of protein kinase activity in humans in need thereof.

The present invention relates to a composition comprising at least one mixture of organic peroxides containing a first organic peroxide of formula (I) and a second organic peroxide, n-butyl-4,4-di(tert-butylperoxy)-valerate. The invention also relates to the use of said composition for crosslinking at least one crosslinkable polymer.

The invention discloses a 4-trimethylsiloxy-5-cyano pentanamide / valerate compound and a preparation method of the 4-trimethylsiloxy-5-cyano pentanamide / valerate compound. The preparation method comprises the following steps: directly starting from non-activated olefin alkenyl silane, firstly, carrying out 1, 3-dipolar cycloaddition reaction on the non-activated olefin alkenyl silane and 1, 1-dibromo formaldoxime under the conditions that potassium carbonate is taken as alkali and ethyl acetate is taken as a solvent to generate 3-bromo-5-(trimethylsilyl)-4, 5-dihydroisoxazole; then, in a nitrogen atmosphere, by utilizing a photooxidation reduction catalysis strategy and by virtue of the capability of capturing halogen atoms of excited state [Au2 (dppm) 2] Cl2, debromination cracking ring opening of the 3-bromo-5-(trimethylsilyl)-4, 5-dihydroisoxazole is realized, and alpha-oxy carbon free radicals can be generated in the next free radical 1, 2-silicon migration process, so that the 3-bromo-5-(trimethylsilyl)-4, 5-dihydroisoxazole can be obtained through debromination cracking ring opening of the 3-bromo-5-(trimethylsilyl)-4, 5-dihydroisoxazole. And the free radical sequentially reacts with acrylamide or acrylic ester and a hydrogen donor to finally obtain the 4-trimethylsiloxy-5-cyano valeramide / valerate compound. The materials required by the method are commercialized or can be prepared through simple organic synthesis, visible light is used as an energy source, the method can be carried out at room temperature, and the method has the characteristics of mild conditions, greenness, environmental protection and the like.

The present application relates to the technical field of phase change material, and provides a phase change cold storage material, a preparation method and application thereof, the phase change cold storage material comprises two or more components; the components comprise ester substances; the ester substances are selected from one or a combination of two or more of butyl valerate, ethyl butyrate and n-propyl acetate. By screening specific ester substances, a mixed medium with a eutectic temperature less than or equal to -90 DEG C can be obtained, so that the energy storage requirement in the temperature zone below -90 DEG C can be realized. The selected substances have the characteristics of high safety and excellent thermal performance, and can be used in the fields of liquefied natural gas storage, liquefied natural gas transportation, medicine storage, medicine transportation or power load management. Meanwhile, the phase change cold storage material preparation method is simple, low in cost and has a high market application prospect.

This invention provides a method for preparing valerate esters by carbonylation of mixed butenes, relating to the field of valerate ester preparation technology. The invention involves pre-preparing a catalyst precursor, ligand, mixed butenes, and an organic solvent with carbon monoxide in a pre-preparation device. The pre-prepared catalyst stream is then continuously fed into a reactor along with mixed butenes, an alcohol, and carbon monoxide for a hydrogen esterification reaction. Simultaneously, a separator separates the valerate ester product, recovers the alcohol, and recycles the catalyst solution. This method achieves efficient and continuous preparation of valerate esters from mixed butenes under mild conditions, offering advantages such as high raw material utilization, long catalyst lifespan, low production cost, and broad prospects for industrial application.

The invention belongs to the field of microorganisms and fermentation engineering, and discloses recombinant escherichia coli for producing valerolactam as well as a construction method and application of the recombinant escherichia coli. The method comprises the following steps: firstly, modularly optimizing the expression level of a heterologous gene and optimizing a whole-cell catalytic reaction system by using promoter engineering; then, the catabolism of pyruvic acid and the synthesis path of L-lysine are modified, and the supply of precursor substances is enhanced, so that the recombinant escherichia coli realizes de novo synthesis of the valerolactam, and the synthesis efficiency of the valerolactam is remarkably improved. Compared with the prior art, the invention not only provides two methods of whole-cell catalysis and de novo synthesis of the valerolactam, but also effectively avoids the problem of environmental pollution generated in the chemical synthesis process, embodies the concept of green synthesis, and ensures that the yield of the valerolactam reaches a higher level even only at a shake flask level. Important application prospects are provided for efficient synthesis of valerolactam.

The application discloses a kind of acetophenone derivatives and preparation method thereof, belong to organic synthesis field.The acetophenone derivative is 1-[3-methoxy-4-(1-ethyl pentyloxy) phenyl] ethanone, its preparation method includes: anhydrous tetrahydrofuran, 3-heptanol, 4-hydroxy-3-methoxy acetophenone and triphenyl phosphine are mixed, then cooling to 0~10 ℃ and keep in this temperature range drop to it azobisdimethyl valerate, after drop completion room temperature reaction 1~24 hours, again after processing is obtained.The application uses the product that can be easily purchased in market as starting material, and uses relatively safe solvent to carry out reaction, obtains higher reaction yield and high product purity, process flow operation is simple and has no harsh reaction condition, can overcome amplification effect, still maintains higher yield and high purity in kg level production, so as to be more suitable for industrialized production application.

The invention is suitable for the technical field of insect repellent drops, and provides a compound long-acting insect repellent drop and a preparation method thereof, the compound long-acting insect repellent drop comprises an active component, a micro-capsule component, a gel component and a proper amount of water, the mass concentration ratio of the active component to the micro-capsule component to a temperature-sensitive phase change component is (15-20): (22-27): (54-60); the active component comprises a main active component, fipronil and amitraz, and the mass concentration ratio of the main active component to fipronil to amitraz is (6-10): (1-3): (0.2-0.9); the microcapsule component comprises an inner core layer, the inner core layer comprises poly (glycerol sebacate) and polyhydroxybutyrate valerate, and the mass concentration ratio of the poly (glycerol sebacate) to the polyhydroxybutyrate valerate is (3-5): (2-5). According to the invention, the drug effect of the insect repellent drop is obviously prolonged to more than 3 months through a microencapsulation technology, the administration frequency is reduced, and meanwhile, the skin irritation is reduced.

The invention discloses a preparation method of a balofloxacin key intermediate 3-methylaminopiperidine dihydrochloride, which comprises the following steps: carrying out intramolecular condensation on 5-amino-2-((t-butyloxycarboryl) amino) valeric acid serving as an initial raw material under the action of a condensing agent, reducing the obtained lactam under the action of a reducing agent, and purifying to obtain the balofloxacin key intermediate 3-methylaminopiperidine dihydrochloride. And finally, salifying to obtain the 3-methylaminopiperidine dihydrochloride. The method is short in process step, simple and convenient to operate and suitable for large-scale industrial production.